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Recent successes in clinical trials have provided important proof of concept that small inter-
fering RNAs (siRNAs) indeed constitute a new promising class of therapeutics. Although
great efforts are still needed to ensure efficient means of delivery in vivo, the siRNA mol-
ecule itself has been successfully engineered by chemical modification to meet initial
challenges regarding specificity, stability, and immunogenicity. To date, a great wealth of
siRNA architectures and types of chemical modification are available for promoting safe
siRNA-mediated gene silencing in vivo and, consequently, the choice of design and modifi-
cation types can be challenging to individual experimenters. Here we review the literature
and devise how to improve siRNA performance by structural design and specific chemical
modification to ensure potent and specific gene silencing without unwarranted side-effects
and hereby complement the ongoing efforts to improve cell targeting and delivery by other
carrier molecules.
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SILENCING GENES USING NUCLEIC ACID
NUCLEIC ACID-BASED THERAPEUTICS
Nucleic acid-based therapeutics promise to overcome the major
limitation of existing medicine, which can currently only tar-
get a limited number of proteins involved in disease pathways
(Melnikova, 2007). Such promise rely on the high predictabil-
ity of nucleic acid base-pairing which provides an ideal frame-
work for gene silencing technologies (GSTs) by offering unpar-
alleled specificity, rapidity of development and renders, at least
in principle, all human genes “druggable”(Krieg, 2011). Pioneer-
ing work in the 1970–1980s established the nucleic acid anti-
sense technology as an universal GST by developing synthetic
antisense oligonucleotides (ASOs) and ribozymes, which base
pair to and inhibit the function of any desired messenger RNA
(mRNA; Zamecnik and Stephenson, 1978; Potera, 2007). Today,
two ASO-based drugs have been commercialized and several
modern antisense design variants (Monia et al., 1993; Highley-
man, 1998; Elmen et al., 2008; Gupta et al., 2010; Cirak et al.,
2011) may be on the verge of success with >50 RNA or RNA-
derived therapeutics reaching clinical testing (Sanghvi, 2011; Bur-
nett and Rossi, 2012). This journey has, however, been far from
straightforward and tedious efforts have been invested to engi-
neer poorly performing drug candidates such as first generation
ASO designs by chemical modification (Stein and Krieg, 1994)
to meet therapeutic standards of potency and safety (Potera,
2007).
EXPLOITING RNAi PATHWAYS FOR THERAPEUTICS
The discovery of RNAi interference (RNAi), gene silencing by
double-stranded RNA (dsRNA), in the nematode worm C. ele-
gans in 1998 (Fire et al., 1998) and the observation in 2001 that
synthetic 21-mer dsRNA, named small interfering RNA (siRNA),
triggered potent and specific gene silencing in mammalian cells
(Elbashir et al., 2001a) provided researchers with an unprece-
dentedly powerful gene silencing tool. The obvious therapeutic
potential of siRNAs immediately renewed the scientific and com-
mercial interest in developing nucleic acid drugs capable of low-
dose, non-toxic targeting of mRNAs to treat human diseases. As
compared to other nucleic acid-based technologies, siRNA bene-
fits from harnessing endogenous RNAi pathways to effectuate gene
silencing (Figure 1); upon introduction of synthetic siRNAs into
the cell cytoplasm they are incorporated into an RNA-induced
silencing complex (RISC; Hammond et al., 2001) by a RISC load-
ing complex (RLC; Maniataki and Mourelatos, 2005) containing
the RNase III enzyme Dicer (Bernstein et al., 2001). By sensing
the thermodynamic asymmetry of siRNA duplex ends (Khvorova
et al., 2003; Schwarz et al., 2003), RLC loads the siRNA guiding
antisense strand into a cleavage-competent RISC containing Arg-
onaute 2 (Ago2; Martinez and Tuschl, 2004), whereas the passenger
sense strand (SS) is cleaved and released (Matranga et al., 2005;
Leuschner et al., 2006). Subsequently, Ago2-RISC will efficiently
guide and effectuate multiple rounds of target RNA cleavage result-
ing in gene “knockdown” (KD; Hutvagner and Zamore, 2002).
Furthermore, the structural similarity of endogenous microRNAs
(miRNAs) and artificial siRNA triggers may be expected to render
these undetectable to cellular sensors of (foreign) dsRNA thereby
preventing induction of innate immune-responses. In effect, har-
nessing siRNA to effectively enter the endogenous RNAi pathway
translates into high silencing efficiencies, predictability, and reli-
ability (Bertrand et al., 2002) but concurrently hold the potential
to disturb endogenous gene regulation by the native inhabitants
of the RNAi pathway, the miRNAs.
siRNA AS A THERAPEUTIC PLATFORM
Small interfering RNAs have gained increasing popularity in vivo
(Behlke, 2006, 2008; Higuchi et al., 2010; Lares et al., 2010)
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FIGURE 1 |The benefits and limitations of synthetic siRNA application.
The most widely used siRNA type is the “canonical” synthetic 21-mer siRNA
composed of two 21 nt RNA strands annealed to form a 19-bp dsRNA duplex
stem and 2 nt 3′-overhangs at both ends (the passenger strand is shown in
black and the guide strand is shown in red). Also synthetic, dicer-substrate
27-mer siRNAs (DsiRNA) has provided a popular alternative. Both design
types can be delivered in vivo either unformulated or upon formulation of
various types of delivery agents into the cell cytoplasm (light gray circle)
where siRNAs are taken up by a RISC loading complex (RLC), which upon a
dicer cleavage event (27-mer designs only, 21-mer siRNAs are
dicer-independent) is structurally rearranged into a pre-RISC. Here the siRNA
passenger strand is cleaved leading to the establishment of an active RISC
that assists and ensures efficient degradation of RNA target sharing perfect
(Continued)
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FIGURE 1 | Continued
sequence complementarity to the siRNA guide stands. A number of
bottleneck in siRNA applications are currently being resolved by
chemical modification strategies (red circles). Unformulated siRNAs
are sensitive to nuclease degradation in extracellular environment
 and, although degradation rates are much lower in the
cytoplasm, siRNAs stabilization by modification is suggested to also
enhance intracellular availability and silencing persistence . Also,
extracellular siRNAs can be rapidly cleared from the body, e.g., by
renal filtration  and can induce innate immune responses via TLR3
in certain cells . Delivery across the target cell membrane  and
endosomal release of endocytosed  are currently the main
bottlenecks in siRNA applications in vivo and siRNAs may induce
TLR7/8-mediated immune-responses upon endosome retention in
immune cells . Also, all cells can respond to foreign cytoplasmic
RNA via the PRRs, PKR, RIG-I, and Mda5 . siRNA may disturb
natural miRNA pathways, that processes nuclear pri-miRNA
transcripts (dark gray circle) via a pre-miRNA intermediate and
miRNA duplex into a single-stranded miRNA in RISC, by direct
competition for RISC loading  or by clotting the pathway due to
slow siRNA processing and turnover . Finally, all siRNA will trigger
miRNA-like off-targeting effects on unintended targets upon
base-pairing of the guide strand seed region and positions within
mRNA 3′ UTRs leading to transcript destabilization and/or
translational repression . Please refer to main text for more
detail.
and the number of RNAi-based preclinical and clinical tri-
als have increased rapidly over recent years with ∼22 differ-
ent siRNA or short hairpin RNA (shRNA) therapeutics reach-
ing clinical testing for the treatment of at least 16 diseases
(http://maps.google.com/maps/ms?ie=UTF8&source=embed&oe
=UTF8&msa=0&msid=117696484602143675789.000476c449bf3
97da6d6c; DeVincenzo et al., 2008; Davis et al., 2010; Leachman
et al., 2010; Burnett et al., 2011; Davidson and McCray, 2011;
Burnett and Rossi, 2012). This is truly an amazing achievement
for a such a fledgling technology considering that conventional
development of small-molecule drugs takes at least 5–7 years for
preparing a single drug candidate for human clinical trials (Krieg,
2011). For comparison, the first clinical trial of a siRNA-based
drug was initiated in 2004 only 3 years after the initial application
of siRNA in mammalian cell cultures (Shukla et al., 2010) and
successful siRNA designs may easily be adaptable to other target.
siRNA NEED CHEMICAL ENGINEERING TO SUCCEED AS THERAPEUTIC
PLATFORM
Building superior siRNAs is a combination of choosing an opti-
mal siRNA-target sequence, optimal type of siRNA design, and,
importantly, to introduce the proper combination of chemical
modifications to suit the particular application. As a scientific
tool in mammalian cell cultures, the potency and specificity of
unmodified synthetic siRNA may be considered sufficient, yet
chemical engineering of siRNAs is a prerequisite to transform
them into a novel class of safe therapeutics, a natural progression
similar to the development of second generation ASO (Potera,
2007). Recent concerns regarding siRNA delivery and safety have
dampened initial excitement and Big Pharma have recently down
sized their investments in RNAi R&D (Ledford, 2010; Krieg, 2011;
Schmidt, 2011). In particular, the size, lability, and negative charge
of siRNAs severely complicate efficient intracellular delivery in vivo
(Meade and Dowdy, 2009) and siRNA may trigger innate immune-
response and lead to unintended deregulation of endogenous gene
expression in several ways, as described in the following sections.
Encouragingly, these concerns may be fully addressable by care-
ful chemical modification of the synthetic siRNA molecule, an
ongoing task that have already gone a long way; the first KD of
an endogenous gene, apolipoprotein B (ApoB), was observed in
mouse livers after low-pressure intravenous injections of a chemi-
cally modified, but naked (non-formulated) siRNA already in 2004
(Soutschek et al., 2004). Also, the first successful KD via RNAi of a
cancer target gene in a human, the M2 subunit of ribonucleotide
reductase (RRM2), was achieved in 2010 upon systemic siRNA
delivery, a holy grail in siRNA therapeutics, using siRNA nanopar-
ticles in a clinical phase-I trial in tumors from melanoma patients
(Davis et al., 2010).
STRUCTURAL siRNA DESIGNS
Today, a variety of siRNA design types are available for gene silenc-
ing each offering benefits and disadvantages (Figure 2): The by far
most popular siRNA design mimics natural Dicer cleavage prod-
ucts and comprises a 21 nucleotide (nt) guiding strand antisense
to a given RNA target and a complementary passenger strand
annealed to form a siRNA duplex with a 19-bp dsRNA stem
and 2 nt 3′ overhangs at both ends (here referred to as canoni-
cal 21-mer siRNAs; Elbashir et al., 2001a,b). Longer design types,
collectively referred to as Dicer-substrate siRNAs (DsiRNAs) struc-
turally mimic various Dicer substrates to enhance incorporation
into RNAi pathways and potentially siRNA potency (Kim et al.,
2005; Rose et al., 2005; Siolas et al., 2005; Amarzguioui et al., 2006;
Collingwood et al., 2008; Hefner et al., 2008; Tanudji et al., 2009).
Also shorter or truncated siRNA designs are gaining popularity
such as 16-mer siRNA (Chu and Rana, 2008), shRNAs with RNA
stems≤19 bp (Ge et al., 2009a,b), blunt 19-bp siRNAs (Czauderna
et al., 2003; Prakash et al., 2005; Hogrefe et al., 2006; Ghosh et al.,
2009), asymmetrical siRNAs (aiRNA; Sun et al., 2008), and asym-
metric shorter-duplex siRNA (asiRNA; Chang et al., 2009). Finally,
fork siRNAs (Hohjoh, 2004; Petrova Kruglova et al., 2010), single-
stranded siRNAs (ss-siRNAs; Martinez et al., 2002; Holen et al.,
2003; Hall et al., 2006), Dumbbell-shaped circular siRNAs (Abe
et al., 2011), bulge-siRNA (Dua et al., 2011), and sisiRNAs (Bram-
sen et al., 2007) have been successfully utilized, but may require
more testing to qualify as a therapeutic siRNA platform. Recently,
siRNAs have also been incorporated in larger nucleic acid struc-
tures (Afonin et al., 2011; Grabow et al., 2011) with the prospect
of enhancing delivery and bio-availability in vivo.
TOLERANCES FOR CHEMICAL MODIFICATION OF siRNAs
The chemical synthesis of siRNAs allows the position-specific
incorporation of chemically modified nucleotides in the siRNA to
modulate, e.g., thermostability, nuclease resistance, duplex struc-
ture, and base-paring properties. For a decade, the compatibility
of a diversity of chemical modifications with siRNA function has
been mapped by empirical testing. Early siRNA chemical modifi-
cation schemes quite naturally focused on modification types pre-
viously used to potentiate and stabilize ASOs (reviewed in Kurreck,
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FIGURE 2 | Popular siRNA design types. The canonical 21-mer siRNA is the
most popular siRNA design today. Dicer-substrate siRNAs such as 27-mer
siRNA, shRNA, pre-miRNA mimics, or fork siRNA may enhance siRNA
potencies. Asymmetrical siRNAs (aiRNA), asymmetric shorter-duplex siRNA
(asiRNA), bulge-siRNAs and sisiRNA may enhance silencing specificity.
Blunt-end siRNA are reported to be more nuclease resistant. Single-stranded
siRNAs (ss-siRNAs) and 16 mer are functional but may required higher siRNA
concentrations. Dumbbell-shaped circular siRNAs may have longer silencing
duration. Passenger strands are shown in black and guide strands in red.
Please refer to main text for more detail.
2003; Wilson and Keefe, 2006) with hopes of similar improvements
in siRNA performance. The toolbox of chemical modification
types seems ever expanding and current efforts should determine
how and which chemical modifications types are best combined
in single siRNAs to simultaneously reduce siRNA immunogenicity
(Sledz et al., 2003), miRNA-like off-targeting (Jackson et al., 2003),
to enhance nuclease resistance/bio-availability in vivo (Soutschek
et al., 2004; Gao et al., 2009; Merkel et al., 2009), and silencing
duration while preserving siRNA potency.
Although effects are naturally rather chemistry-specific, the
positional tolerance for chemical modification of siRNAis fairly
established (Elbashir et al., 2001b; Chiu and Rana, 2002, 2003;
Hamada et al., 2002; Amarzguioui et al., 2003; Braasch et al., 2003;
Czauderna et al., 2003; Grunweller et al., 2003; Harborth et al.,
2003; Prakash et al., 2005; Choung et al., 2006; Bramsen et al.,
2009). As a general trend, the entire passenger strand as well as
the 3′-proximal part and 3′ overhang of the guiding stand is most
tolerant to chemical modification, which agrees with the observa-
tion that only position 2–16 of the guide strand base pairs with
its target prior to cleavage (Wang et al., 2009b). The siRNA 3′
overhang of the guide strand, which is bound by the Ago PAZ
domain during loading, is conveniently tolerant to chemical mod-
ification. This reflects a limited role of PAZ binding during target
cleavage (Ma et al., 2004) where the 3′ overhang is released from
the PAZ domain (Tomari and Zamore, 2005; Wang et al., 2009b).
This renders siRNA 3′ overhangs relatively safe to modify, even
with bulky modifications incompatible with the size of the PAZ
binding pocket.
In contrast, the 5′ phosphate, the 5′-proximal part, and central
positions of the guide strand are sensitive, especially to multi-
ple, thermo-modulating, or bulky modifications that influence the
properties of minor groove. These tolerances agree nicely with the
structure of the Ago2-guide strand complexes; Here the 5′ phos-
phate of the guide strand is consistently found in the Ago MID
domain (Wang et al., 2008), an essential interaction for strand
loading into RISC (Nykanen et al., 2001; Lima et al., 2009). Once
bound by Ago2, the initial interactions between the guide strand
and target RNA is mediated only by the 5′ proximal siRNA seed
region (positions 2–8 of the RISC-associated strand) selectively
exposed to the solvent (Wang et al., 2008) and subsequent Ago2-
mediated cleavage of target RNA requires forming of an RNA-like
A-type helix structure between the guide strand and the target
spanning both the seed region and around the cleavage site (oppo-
site of guide strand position 10/11; Meister et al., 2004) hereby
explaining the sensitivity of these AS positions to modification.
TOOLS FOR CHEMICAL MODIFICATION OF siRNAs
Mainly four classes of chemical modifications is utilized to modify
ASOs and now siRNAs: (i) modification of the negatively charged
phosphodiester backbone is primarily utilized to enhance siRNA
nuclease resistance or affect RNA biodistribution and cellular
uptake; (ii) modifications at the ribose 2′-OH group is widely
used to modulate most aspects of siRNA behavior including mod-
ulating siRNA nuclease resistance, potency, specificity of silencing
and to reduce siRNA immunogenicity; (iii) modifications of the
ribose ring and nucleoside base is utilized to modulate siRNA sta-
bility and base-pairing properties; (iv) dual modifications harbor
two modified functionalities in a single nucleotide and especially
the combination of backbone and ribose modifications with 2′
OH substitutions are currently gaining momentum (for a non-
exhaustive selection of popular chemical modification types in
siRNA design see Figure 3).
siRNA BACKBONE MODIFICATION
A classic and popular phosphate backbone alteration is the phos-
phoromonothioate (PS) modification where one of the non-
bridging phosphate oxygens is replaced with sulfur (Braasch et al.,
2004). Also phosphorodithioate (PS2) substitutions, where both
non-bridging oxygen atoms are replaced, were recently tested in
siRNA designs and slightly increased siRNA potencies and nucle-
ase resistance as compared to PS and unmodified siRNA (Yang
et al., 2012). Moderately PS-modified siRNAs support efficient
RNAi, yet effects are very position-dependent (Amarzguioui et al.,
2003; Braasch et al., 2003; Chiu and Rana, 2003; Grunweller et al.,
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FIGURE 3 | Popular chemical modification types in siRNA design. RNA,
ribonucleic acid; PS, phosphothioate; PS2, phosphodithioate; EA,
2′-aminoethyl; DNA, deoxyribonucleic acid; 2′-F, 2′-fluoro; 2′-OMe 2′-O-methyl;
2′-MOE, 2′-O-methoxyethyl; F-ANA, 2′-deoxy-2′-fluoro-β-d-arabinonucleic acid;
HM, 4′-C -hydroxymethyl-DNA; LNA, locked nucleic acid; carboxylic LNA,
2′,4′-carbocyclic-LNA-locked nucleic acid; OXE, oxetane-LNA; UNA, unlocked
nucleic acid; 4′-S, 4′-thioribonucleis acid; F-SRNA,
2′-deoxy-2′-fluoro-4′-thioribonucleic acid; ME-SRNA,
2′-O-Me-4′-thioribonucleic acid; 4′-S-F-ANA, 2′-fluoro-4′-thioarabinonucleic
acid; ANA, altritol nucleic acid; HNA, hexitol nucleic acid; B, base.
2003; Harborth et al., 2003; Choung et al., 2006) but extensive
PS modification reduces silencing (Chiu and Rana, 2003; Hall
et al., 2004) and has toxic side-effects (likely due to a tendency to
bind non-specifically to cellular membrane proteins; Amarzguioui
et al., 2003; Harborth et al., 2003). Still, moderate PS modifi-
cation levels have been widely and successfully combined with
ribose 2′-OH modifications in both ASO and siRNA designs to
stabilize naked RNA for systemic application in mice (Soutschek
et al., 2004; Elmen et al., 2008). Both PS and PS2 will slightly
thermo-destabilize siRNA duplexes (∼0.5˚C per modification;
Eckstein, 2002; Amarzguioui et al., 2003; Harborth et al., 2003;
Yang et al., 2012). Substitution of the phosphodiester linkage with
a boranophosphate linkage have been explored in gene silencing
using a canonical siRNA (Hall et al., 2004) or single-stranded siR-
NAs (Hall et al., 2006). Similarly to PS and PS2, boranophosphate
linkages decrease the Tm of RNA duplexes by ∼0.5–0.8˚C per
modification (Li et al., 2007) and enhances nuclease resistance as
compared to unmodified siRNAs, yet is better-tolerated in siRNA
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design than PS (Hall et al., 2004). Still this modification type has
not been widely used.
A phosphonoacetate (PACE) modification consists of an acetate
group in place of a non-bridging oxygen in an internucleotide
phosphate linkage whereas a thioPACE modification is an anal-
ogous substitution in a phosphorothioate linkage. Both mod-
ifications are completely resistant to degradation and PACE is
electrochemically neutral if esterified with, e.g., methyl groups
(Sheehan et al., 2003), which allows modified oligonucleotides to
be taken up by cells in the absence of delivery reagents (Yamada
et al., 2007). Also dual modification types combining 2′-OMe
and PACT/ThioPACT have recently been tested in siRNA design
(see below). Finally, amide linkages (Iwase et al., 2007) and 2′,5′-
linkages (Prakash et al., 2006) have been found to enhance nuclease
resistance of siRNAs, yet are little used so far.
RIBOSE 2′-OH SUBSTITUTIONS
Modifications of the ribose 2′-OH is the most popular approach
in siRNA design in which the 2′-OH is either substituted with
other chemical groups or the 2′-oxygen is “locked” via intramol-
ecular linkages as in bridged nucleic acids (BNAs). So far, the
small electronegative 2′ substituents such as 2′-fluoro (2′-F), DNA
(2′-H), 2′-O-methyl (2′-OMe) are most widely used as they are
well-tolerated, will generally enhance siRNA nuclease resistance
and not dramatically affect siRNA thermostability, dsRNA duplex
conformation nor siRNA activity.
Fluorine substitution (2′-F) slightly stabilizes dsRNA duplexes
(∼1˚C increase inTm per modification; Freier and Altmann, 1997;
Allerson et al., 2005), is among the best tolerated modification
types and therefore allows the creation of highly modified, active
siRNAs: both strands tolerate 2′-F modification at most positions
(Braasch et al., 2003; Chiu and Rana, 2003; Harborth et al., 2003;
Prakash et al., 2005; Choung et al., 2006; Manoharan et al., 2011)
and substitution of all siRNA pyrimidines was reported to greatly
enhance serum stability and to support effective silencing in vitro
and in vivo (Capodici et al., 2002; Layzer et al., 2004; Morrissey
et al., 2005a). Also, 2′-F has proven superior during an applica-
tion in vivo using a mouse model for silencing of the factor VII
gene as directly compared to other 2′ OH modifications types such
as the popular 2′-OMe (Manoharan et al., 2011). Even fully sub-
stituted siRNA containing alternating modifications of 2′-F and
DNA (Blidner et al., 2007) or 2′-OMe (Allerson et al., 2005) can
be both highly potent and nuclease resistant.
Similarly to 2′-F, the naturally occurring 2′-OMe modification
was among the first and most extensively tested 2′-substitutions
(Amarzguioui et al., 2003; Chiu and Rana, 2003; Czauderna et al.,
2003; Grunweller et al., 2003; Prakash et al., 2005; Choung et al.,
2006; Jackson et al., 2006a); 2′-OMe slightly enhances the binding
affinity toward RNA (Tm increase of 0.5–0.7˚C per modification)
and is well-tolerated in most duplex positions (Freier and Alt-
mann, 1997; Kraynack and Baker, 2006), although less so than
2′-F in the guide strand. More extensive or full modification, par-
ticularly of the guide strand seed region, can reduce siRNA potency
(Elbashir et al., 2001a; Braasch et al., 2003; Chiu and Rana, 2003;
Czauderna et al., 2003) although conflicting results suggest that
tolerances are siRNA sequence-dependent (Choung et al., 2006;
Kraynack and Baker, 2006). Traditionally, 2′-OMe modification
has been extensively used to increase siRNA nuclease resistance
and proven particular successful in combination with other 2′-
modifications, e.g., 2′-F, to generate fully substituted, nuclease
resistant, yet functional siRNAs (Allerson et al., 2005). Also, par-
tially 2′-OMe/PS-modified siRNA conjugated with cholesterol was
the first chemical design to successfully silence an endogenous gene
in mice using a systemic delivery strategy suitable for therapeu-
tics (Soutschek et al., 2004). More recently 2′-OMe modification is
also gaining popularity for reducing siRNA immunogenicity and
off-targeting (see Reducing siRNA Immunogenicity by Chemical
Modification and Reducing siRNA Off-Target Effects by Chemical
Modification).
DNA modification, typically dTdT, has long been the industry
standard for modifying siRNA 3′ overhangs to reduce cost, while
conferring nuclease resistance (Elbashir et al., 2001a) and preserv-
ing siRNA potency (Braasch et al., 2003; Chiu and Rana, 2003).
As for 2′-F and 2′-OMe, DNA is well-tolerated in the passenger
strand with little effect on siRNA potency (Hogrefe et al., 2006;
Pirollo et al., 2007). Similarly to 2′-OMe, only partially DNA sub-
stituted guide strands are functional (Parrish et al., 2000; Chiu
and Rana, 2003) whereas alternating the DNA modification with
2′-F has created fully substituted, active guide strands (Chiu and
Rana, 2003). Notably, full DNA substitution of the guide strand
seed region can reduce off-target effects (see Reducing siRNA Off-
Target Effects by Chemical Modification) albeit its influence on
siRNA potencies may be somewhat sequence-dependent (Ui-Tei
et al., 2008) and dTdT overhangs seem to reduce silencing duration
(see Strapps et al., 2010; Enhancing Silencing Duration).
More bulky 2′-modifications such as 2′-O-MOE, 2′-O-allyl and
others are only tolerated at certain positions within the siRNA
duplex, likely owing to their distortion of RNA helix structure
essential to Ago2 cleavage (Amarzguioui et al., 2003; Prakash
et al., 2005; Odadzic et al., 2008; Bramsen et al., 2009). This
somewhat limits their use for general siRNA design as similar
enhancements in, e.g., nuclease resistance may be obtained by
the better-tolerated, smaller 2′ substitutions described above. Still,
bulky 2′-modifications are best tolerated at the 3′-ends of siRNA
strands (Odadzic et al., 2008), where they may be used to mod-
ulate thermodynamic stability and duplex asymmetry to enhance
siRNA potency: e.g., an 2′-aminoethyl modification in the passen-
ger strand 3′-end can enhance siRNA potency, likely by affecting
strand selection during RISC loading (Bramsen et al., 2009). Still,
bulky 2′-modifications are not widely used other than in siRNA
overhangs to enhance nuclease resistance (Amarzguioui et al.,
2003; Prakash et al., 2005; Odadzic et al., 2008; Bramsen et al.,
2009).
BRIDGED NUCLEIC ACIDS
Another class of 2′-modification is the BNA in which the ribose
2′-oxygen is linked to the 4′-carbon via a methylene bridge as in
Locked Nucleic Acid (LNA; Wengel et al., 2001) and carbocyclic-
LNA (Srivastava et al., 2007; Bramsen et al., 2009), via an ethylene
bridge as in ethylene-bridged nucleic acid (ENA; Hamada et al.,
2002) and carbocyclic-ENA (Srivastava et al., 2007; Bramsen et al.,
2009), or to the 1′-carbon as in oxetane (OXE; Pradeepkumar et al.,
2003; Bramsen et al., 2009). This radical modification type gen-
erates nucleotides with interesting properties to siRNA design;
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The methylene bridge in the very popular LNA-modification
locks the sugar moiety in the RNA-helical C3′-endo conformation,
which additively increase RNA duplex thermostability by 2–10˚C
per LNA (Petersen and Wengel, 2003). Although this dramatic
thermo-stabilization limits siRNA modification levels by LNA
(Braasch et al., 2003; Grunweller et al., 2003; Elmén et al., 2005),
it provides unique opportunities to modulate the local thermody-
namic profile within the siRNA duplex to optimize strand selection
and thereby enhance specificity (Elmén et al., 2005; Bramsen et al.,
2007, 2009), to enhance nuclease resistance in vitro (Braasch et al.,
2003; Bramsen et al., 2009) and in vivo (Mook et al., 2007; Glud
et al., 2009) and reduce siRNA immunogenicity (Hornung et al.,
2005) as described in the following sections. Also, the thermo-
stabilizing LNA may be used to ensure the integrity of siRNA
designs relying on only short regions of oligo base-pairing such
as the three stranded sisiRNA design (Bramsen et al., 2007). As a
note of caution, LNA-modified ASO scan induce profound hepa-
totoxicity in mice (Swayze et al., 2007) albeit this is not observed
in other studies, e.g., in primates (Elmen et al., 2008).
ALTERATION OF THE RIBOSE MOIETY
Modification types based on sugar moieties other than ribose have
been successfully used in siRNA designs upon incorporation of,
e.g., altritol nucleic acid (ANA), hexitol nucleic acid (HNA), 2′-
deoxy-2′-fluoroarabinonucleic acids (2′-F-ANA), and cyclohex-
enyl nucleic acid (CeNA) nucleotides, which are based on altritol,
hexitol, arabinose, and cyclohexenyl sugars, respectively (Dowler
et al., 2006; Fisher et al., 2007, 2009; Nauwelaerts et al., 2007; Watts
et al., 2007; Bramsen et al., 2009).
The 2′-F-ANA modification is structurally similar to DNA
(C2′-endo conformation) and increases the Tm of the siRNA
duplex by∼0.5–0.8˚C per modification and will, due its structural
similarity to DNA, structurally distort siRNA duplexes making it
little suited to modify the seed regions of the guide strand. Full
modification of the SS can lead to significant enhancements in
potency and nuclease resistance and 2′-F-ANA-modification may
be particular useful in the guide strand to create high-affinity 3′
overhangs, similarly to DNA (Dowler et al., 2006; Watts et al.,
2007). Moreover, heavily modified siRNAs that contain combi-
nations of 2′-F-ANA and 2′-F or LNA show superior properties
(Deleavey et al., 2010).
The ANA modification will slightly enhance siRNA thermosta-
bility, are stable against enzymatic degradation and can moderately
enhance siRNA activity and silencing duration upon incorpo-
ration into of both duplex 3′-ends (Fisher et al., 2007) whereas
overhang modification slightly decrease RISC affinity (Maiti et al.,
2011). Similarly, the incorporation of HNA at both strand 3′-ends
enhanced silencing potency, serum stability, and silencing dura-
tion of a siRNA against B-Raf, even more so than observed for
ANA-modifications upon direct comparison (Fisher et al., 2009).
Finally, CeNA modification of passenger and guide stand 3′-ends
can increase siRNA potency and nuclease resistance (Nauwelaerts
et al., 2007).
A radical modification of the ribose is found in unlocked
nucleic acid (UNA) which is an acyclic derivative of RNA lacking
the C2′–C3′-bond of the ribose ring that still structurally mimic
unmodified RNA upon incorporation into RNA duplexes. Rather
uniquely, the incorporation of UNA residues strongly destabilizes
the duplex by 5–8˚C per UNA monomer hereby allowing dramatic
local destabilization of siRNA duplex and guide strand/target
interactions (Langkjær et al., 2009). As a consequence, exten-
sive UNA modification will prevent annealing of siRNA strands
and limits modification levels to 2–3 UNAs within the duplex
region (Laursen et al., 2010). Still, even modest UNA modifica-
tion has proven very successful in enhancing siRNA biostability
and function in vivo (Laursen et al., 2010), in preserving the
potency of extensively thermo-stabilized siRNA (such as in exten-
sively LNA-modified siRNAs; Laursen et al., 2010) and in reducing
siRNA off-targeting (Bramsen et al., 2010; Vaish et al., 2011)
as described in Section “Reducing siRNA Off-Target Effects by
Chemical Modification.”
Finally, 4′-thio-modified nucleotides (4′-S RNA) contain a sul-
fur atom instead of the 4′-carbon of the ribose ring and can
enhance nuclease resistance, target affinity, and siRNA potency.
Stretches of 4′-thio-RNA were well-tolerated in both siRNA
strands albeit only at certain positions in the guide strand (Hoshika
et al., 2005; Dande et al., 2006) and sequence-specific effects of
4′-thio modifications have been reported (Hoshika et al., 2007).
Instead, 4′-thio-RNA can be utilized as a “dual modification” by
combining it with 2′-OMe (Dande et al., 2006) or 2′-F (Takahashi
et al., 2009), as described below.
BASE MODIFICATION
Chemical modification of the RNA nucleobases is still less com-
monly used in siRNA design (reviewed in Peacock et al., 2011). A
number of modified nucleotide bases, such as 5-bromo-, 5-iodo-,
2-thio-,4-thio-,dihydro-,and pseudo-uracil,have been tested with
the prospect of to stabilize base-pairing and to enhance base par-
ing specificity; 5-bromo- and 5-iodo-uracil slightly reduced siRNA
potency (Chiu and Rana, 2003), whereas 2-thio- and pseudo-uracil
were reported to enhance siRNA potency (Sipa et al., 2007) and to
reduce cellular immune responses (Hornung et al., 2006).
DUAL MODIFICATIONS
The combination of two modified functionalities on a single ribose
in so-called “dual modification” types has recently been tested in
siRNA design to address that 2′-modification or backbone modi-
fication alone typically confers insufficient nuclease resistance and
pharmacokinetic properties for siRNA applications in vivo.
The 4′-Thio (4′-S) modification has been combined with a
variety of 2′-substitutions such as 2′-OMe, 2′-O-MOE, 2′-F, or
2′-F-ANA (Dande et al., 2006; Watts et al., 2007; Takahashi et al.,
2009); Most significantly, 2′-OMe/4′-S modification can signifi-
cantly enhance serum stability as compared to 2′-OMe (or 2′-F)
modification alone and does not affect duplex thermostability,
whereas 2′-F-ANA/4′-S increase theTm by∼1˚C per modification
but does not improve serum stability beyond simple 2′-OMe mod-
ification (Takahashi et al., 2009). Recently, 2′-OMe/4′-S modifica-
tion was shown to significantly enhance siRNA silencing longevity,
an effect that was attributed to enhanced intracellular siRNA sta-
bility (Takahashi et al., 2012). The 2′-F-ANA/4′-S modification,
which decreases the Tm∼ 1.0–1.4˚C per modification, is only tol-
erated at low modification levels and does not immediately offer
unique advantages in siRNA potencies (Watts et al., 2007).
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Combining 2′-OMe and PS modification to create 2′-OMePS
has generated fully modified passenger strands with dramatically
enhanced nuclease resistance whereas similar modification ren-
dered guide strands inactive (Kraynack and Baker, 2006). This
remarkable nuclease resistance seems well suited for ASO design:
in a phase-I clinical trial, the 2′-OMePS-modified ASO, PRO051,
could successfully restore specific exon skipping during mRNA
splicing leading to restoration of dystrophin expression in patients
with Duchenne’s muscular dystrophy (van Deutekom et al., 2007).
Combination of 2′-OMe and PACT or thioPACT linkages
decrease the Tm of RNA duplexes ∼0.75–1˚C per modification
as compared to 2′-OMe-modified duplexes alone (which are sta-
bilized compared to unmodified dsRNA; see above; Threlfall et al.,
2012). PACT and ThioPACT enhance siRNA stability, and will
reduce siRNA potency, even if only placed in the passenger strand,
and (double-stranded) siRNA are not efficiently taken up by cells
in the absence of transfection reagents, in contrast to modified
single-stranded oligonucleotides (Threlfall et al., 2012). Finally,
4′-aminomethyl-2′-OMe dual modification of siRNAs will slightly
lower the Tm (∼1˚C/modification) compared to the unmodified
duplex, can increase siRNA serum stability and modifications are
well-tolerated at various positions in the passenger strand, but not
in the seed region of the guide strand (Gore et al., 2012).
DESIGNING POTENT siRNAs BY CHEMICAL ENGINEERING
A natural priority in siRNA design is to ensure maximal gene
silencing at low concentrations, i.e., to obtain IC50 values in the
nano or pico-molar range suitable for silencing in vivo, where
siRNA delivery is often difficult. Important knowledge of the most
influential factors for siRNA potency has been obtained by empir-
ical testing of large libraries of unmodified siRNAs in cell culture
and subsequent bio-informatical data mining (Reynolds et al.,
2004; Huesken et al., 2005; Vert et al., 2006; Ladunga, 2007; Klin-
gelhoefer et al., 2009; Wang et al., 2009a). Several studies propose
nucleotide base preferences at selected positions relative to the tar-
get sequence such as G/C at position 1, A/U at positions 10 and 19,
more than three A/Us between positions 13 and 19 (Amarzguioui
and Prydz,2004; Reynolds et al., 2004; Ui-Tei et al., 2004; Jagla et al.,
2005), and position-independent overrepresentation of certain
di- and tri-nucleotide motifs (Ebalunode et al., 2011), and rela-
tively U-rich antisense strands (Ladunga, 2007; Wang et al., 2010),
especially in the 5′-end (Ui-Tei et al., 2004). An obvious ques-
tion is whether chemical modification can enhance the potencies
of already well-designed unmodified siRNAs. Indeed, numerous
studies report the improvement of siRNA potency by chemical
modification; typically improvements in potency are moderate,
less than twofold, and only in few cases has chemical modifica-
tion led to dramatic enhancements of siRNA potency (Allerson
et al., 2005), effects, which may be too sequence-specific for general
siRNA design (Koller et al., 2006). Hereby chemical modifica-
tion strategies may not necessarily create “super-potent” siRNAs
(as compared to well-designed unmodified siRNAs), but can be
efficiently used to counteract reductions in potency encountered
while addressing other siRNA shortcoming in siRNA stability,
off-targeting, immunogenicity, or to tweak siRNA thermodynam-
ics when targeting a defined target with a non-optimal sequence
composition.
MODULATING siRNA THERMOSTABILITY AND -ASYMMETRY TO
ENHANCE siRNA POTENCY
Of interest to siRNA chemical modification strategies it is notable
that most of the siRNA sequence preferences described above may
reflect an optimal siRNA thermodynamic profile that ensures effi-
cient handling by RNAi proteins. Most prominently, siRNA strand
selection during RISC activation is determined by the thermody-
namic asymmetry between siRNA duplex ends: the siRNA strand
having its 5′-end embedded at the thermodynamically least sta-
ble end is preferentially employed as guide stand within RISC
(Khvorova et al., 2003; Schwarz et al., 2003). Consequently, siR-
NAs should be designed to be thermodynamically asymmetric
either by simply choosing AU base pairs at the 5′ terminal posi-
tions of the guide stand and/or GC base pairs in its 3′-end or,
more advanced, by engineering proposed optimal difference in
Gibbs free energy between duplex ends (Khvorova et al., 2003;
Shabalina et al., 2006), either by sequence choice or by introduc-
ing mismatches or chemical modifications. In this regard, many
chemical modification types are ideal tools to position-specifically
modulate siRNA thermostability; modifications such as LNA, 2′-F,
2′-OMe are stabilizing, whereas other such as UNA, OXE, and PS
are destabilizing. Chemical screens have identified that modifica-
tions ensuring preferential loading of the intended guide strand
into RISC will often enhance potency; destabilizing modifica-
tion in the passenger duplex 3′-end such as OXE, ethylamino,
UNA, dihydrouracil, or PS (Elmén et al., 2005; Li et al., 2005;
Bramsen et al., 2009; Yang et al., 2012) and stabilizing modifica-
tion in the passenger strand 5′-end such as LNA (Elmén et al.,
2005) and/or stabilizing modification in the guide strand duplex
3′-end improve siRNA potency (Bramsen et al., 2009). For this
purpose, highly stabilizing or destabilizing chemical modifica-
tions are not frequently used in the guide strand seed region as
they can dramatically reduce siRNA efficiency (Bramsen et al.,
2009). It is indeed likely that most of the modification schemes
proposed to moderately enhance siRNA potencies by modify-
ing strand 3′-ends is indeed ensuring optimal thermodynamic
asymmetry.
The thermo-stability profile of the internal part of the siRNA
duplex seem also important as it influences rates of siRNA duplex
unwinding during RISC loading and target RNA release; Design
of a relatively loose siRNA duplex with an overall GC-content
of 30–50% has been common practice (Wang et al., 2009a), yet
more recently Gibbs free energy calculations by the nearest neigh-
bor method has predicted efficient siRNAs and an energy cut-off
(∆G<−34.6 kcal/mol) was introduced to reject too thermo-
stable siRNAs (Ichihara et al., 2007). It remains, however, to be
fully established if the preference for GC-poor siRNAs may rather
indirectly reflect a higher accessibility of AU-rich target sites within
the structured mRNA; in fact, target site accessibility is suggested
to be more important to siRNA efficiency than GC-content per se
(Chan et al., 2009).
A few studies have devised how the activity of too thermo-stable
and therefore little potent siRNA, typically seen upon extensive
LNA, 2′-OMe/2′-F modification, can be rescued by introducing
counteracting modifications like destabilizing UNA modification
(Laursen et al., 2010) or introducing a nicked passenger strand as
in the so-called sisiRNA design (Bramsen et al., 2007).
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ENHANCING siRNA POTENCY BY siRNA OVERHANG MODIFICATION
Preferential guide strand loading into RISC can also be helped
by modifying the canonical siRNA 2 nt 3′ overhangs, which are
bound by the PAZ domain Ago during RISC loading (Ma et al.,
2004). The PAZ domain was originally described to bind siRNA
overhangs in a sequence unspecific manner (Lingel et al., 2004;
Ma et al., 2004), yet siRNA overhang composition does influence
their affinity for the Ago2 PAZ domain and siRNA potencies: par-
ticularly the UU overhang has high affinity for the PAZ domain
but is concurrently easily dissociated from the PAZ domain upon
strand cleavage (Lee et al., 2007). In agreement, superior silenc-
ing of siRNA with UU overhang as compared to AA, GG, and
CC has been reported (Elbashir et al., 2001b). Hereby, differ-
ential use of UU in the guiding strand and GG, CC pairs in
the passenger strand should ensure preferential loading of the
guide strand into RISC. Also, the siRNA overhangs can, due
to base stacking, contribute nearly the same to the thermody-
namic stability as a regular base pair (O’Toole et al., 2005) and
thereby help to direct siRNA strand selection by altering the
siRNA thermodynamic asymmetry, a somewhat overlooked strat-
egy. Finally, preferential guide strand loading into RISC can be
helped by chemically modifying the siRNA 3′ overhangs hereby
providing a sequence-independent, general strategy for enhanc-
ing siRNA performance. Modification types such as DNA, LNA,
UNA, etc. that favor or disfavor strand selection during RISC
loading have been identified and can be used in the guide and
passenger strand, respectively, to enhance siRNA potency and
specificity (Elbashir et al., 2001b; Dowler et al., 2006; Bramsen
et al., 2009).
DESIGNING NUCLEASE RESISTANT siRNAs BY CHEMICAL
ENGINEERING
The general high susceptibility of single-stranded RNA to ribonu-
clease degradation (Tsui et al., 2002) and initial observations
that unmodified siRNAs are subject to relatively fast serum
degradation (Czauderna et al., 2003; Choung et al., 2006) sug-
gested that siRNA would need chemical stabilization to suc-
ceed as a systemically applied RNA therapeutic. Indeed, the
subsequent observation that chemical stabilization was essen-
tial for successful silencing by unformulated siRNAs following
intravenous injection in mice only consolidated this point and
made chemical stabilization a integral part of siRNA engineer-
ing. In essence, however, chemical stabilization is little needed
for typical siRNA applications in cell culture where commer-
cial transfection reagents will shield the siRNAs from serum
RNases. In a therapeutic setting siRNA may also only need
extensive chemical stabilization if exposed to extracellular envi-
ronments such as the blood stream, digestive tract, lung, or
skin, in particular if delivered unformulated, and modification
strategies for formulated siRNAs need rather focus on reducing
siRNA immunogenicity, off-targeting without jeopardizing silenc-
ing potency/duration. Still, chemical stabilization may enhance
silencing duration (see Enhancing Silencing Duration) and appli-
cation of naked, chemically modified siRNA is still a popu-
lar approach with both formulated and unformulated siRNAs
currently undergoing pre- and clinical investigation (Schmidt,
2011).
SEQUENCE-SPECIFIC siRNA DEGRADATION BY EXTRACELLULAR
RIBONUCLEASES
Compared to ssRNA, dsRNAs are rather poor substrates for most
RNases and siRNA degradation is highly sequence-dependent
upon incubation in blood serum, a popular mimic of “extracel-
lular” conditions in vivo (Choung et al., 2006; Haupenthal et al.,
2006; Hong et al., 2010). Here siRNA degradation is mediated pri-
marily by RNase A-like activities (Haupenthal et al., 2006, 2007;
Turner et al., 2007) that, being pyrimidine-specific endonucleases,
cleave dsRNA at specific dinucleotide motifs such as UpA, CpA,
and UpG (Qiu et al., 1998; Sorrentino, 1998; Turner et al., 2007;
Volkov et al., 2009). Recent efforts have characterized siRNA degra-
dation products to identify particularly vulnerable sequence-motif
and indeed degradation in serum occur at only few sites, primarily
at UA and CA dinucleotides (Choung et al., 2006; Turner et al.,
2007; Volkov et al., 2009). It is still not fully clear how the siRNA
thermodynamic stability influences endonuclease resistance; sem-
inal RNases are reported to recognize vulnerable single-stranded
regions exposed from the duplex by thermal fluctuations predict-
ing that thermo-stable siRNA would be more nuclease resistant. In
accordance, thermodynamically “loose” regions within the siRNA
duplex, which is deliberately introduced in the siRNA by design
to ensure guide strand RISC loading, are reportedly more prone
to nuclease attack than thermodynamically more stable regions
(Haupenthal et al., 2006). In contrast, a comprehensive study
found no general thermodynamic difference between the vul-
nerable regions and the remaining siRNA and that both strands
were cleaved simultaneously (almost exclusively at UA and CA
motifs) arguing against recognition of exposed single-stranded
motifs (Hong et al., 2010). These discrepancies aside, avoidance or
modification of UA and CA motifs within the duplex stem is an
attractive strategy to enhance endonuclease resistance.
Notably, blunt-ended siRNA are reportedly more stable in
serums than their canonical counterparts (Czauderna et al., 2003)
leading to the suggestion that exo-nucleases are dominant medi-
ators of siRNA degradation in serum (Soutschek et al., 2004).
However, latter studies report little indications for high exonucle-
ase activity in serum (Haupenthal et al., 2006; Turner et al., 2007)
and propose that the siRNA 2 nt 3′ overhangs may reduce siRNA
stability in serum by allowing ribo-endonucleases to dock on the
siRNAs (Haupenthal et al., 2006). In any case, chemical modifica-
tion of siRNA overhangs is a popular approach to slightly enhance
siRNA nuclease resistance as described below.
INTRACELLULAR siRNA STABILITY
Small interfering RNAs are far more stable once inside the cell and
silencing can last 30–90 days in slowly or non-dividing cells (Song
et al., 2003; Bartlett and Davis, 2007); It is likely that some sta-
bility is gained upon incorporation into RNAi protein complexes
such as RISC, however, double-stranded siRNAs are reported to be
quite stable intracellular in contrast to their corresponding single
strands (Raemdonck et al., 2006). Still, the 3′ exonuclease Eri-1
(Kennedy et al., 2004; Takabatake et al., 2007) has been described
as a key mediator of intracellular siRNA degradation and high
doses of siRNA can enhance Eri-1 levels suggesting that the RNAi
machinery may be controlled by a negative feedback mechanism
(Hong et al., 2005; Bian et al., 2011).
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ENHANCING siRNA NUCLEASE RESISTANCE BY CHEMICAL
MODIFICATION
The most common route of non-specific degradation, which is
also catalyzed by several nucleases, involves a nucleophilic attack
of the ribose 2′-OH and hydrolysis of the interphosphate linkage
via a 2′,3′-cyclic phosphate intermediate (Usher, 1969). Therefore,
siRNA nuclease resistance is enhanced by modifying the ribose
2′OH groups or the internucleotide phosphate linkage. As exten-
sive chemical modification tends to reduce siRNA potencies the
challenge is to identify modification schemes that balance stability
and silencing potency in respect to the specific delivery strategy,
e.g., siRNA formulation and delivery route.
With the assumption that more modifications would gener-
ate better serum stability, early efforts to prepare siRNA for naked
systemic delivery aimed to maximize the number of modified posi-
tions within siRNA duplex. Especially, the combination of mod-
erate phosphoromonothioate (PS) backbone modification with
small, well-tolerated 2′ substitutions (2′-F, 2′-OMe, and 2′-H) or
even fully modified siRNAs have often created highly stable siRNA
for applications in vivo (Soutschek et al., 2004; Allerson et al., 2005;
Morrissey et al., 2005b; Zimmermann et al., 2006; Blidner et al.,
2007; Nishina et al., 2008). In some cases, modification schemes
can be very complex; a successful example is a siRNA having a pas-
senger strand with 2′-F substitutions on all pyrimidine positions,
DNA in all purine positions, 5′ and 3′-inverted abasic end caps and
a guide strand with 2′-F substitutions in all pyrimidine positions,
2′-OMe substitutions of all purines and a single PS modification at
the 3′ terminal linkage that produced dose-dependent gene silenc-
ing upon intravenous injection in mice (Morrissey et al., 2005b).
Extensively modified siRNA is still the norm for systemic admin-
istration and future commercial siRNA therapeutics may likely be
fully modified siRNA harboring complex modification schemes,
at least if not protected by formulation. Yet, for general siRNA
design, complicated modification schemes hold the obvious pitfall
of dramatically reducing siRNA functionality and siRNA sequence
dependencies are not always fully understood. Also, researches may
find the task of testing multiple heavily modified siRNAs to iden-
tify potent candidates for applications in vivo both technically and
financially challenging.
The recent pinpointing of siRNA dinucleotides vulnerable to
nuclease attack suggest that their selective chemical modifica-
tion may represent a general strategy to greatly enhance siRNA
nuclease resistance while preserving siRNA potency (Turner et al.,
2007; Armstrong et al., 2008; Volkov et al., 2009). Typically, the
well-tolerated 2′-OMe and 2′-F modifications are used within
the duplex stem to modify UA and CA motifs and can dramat-
ically improve nuclease resistance with little impact on siRNA
potency (Turner et al., 2007; Armstrong et al., 2008; Volkov et al.,
2009; Hong et al., 2010). Also, as siRNA 3′ overhangs are stabi-
lized by most modification types, these may well be chosen to
simultaneously ensure preferential loading of the guide strand
(see above), e.g., the LNA modification proposed by Bramsen
et al. (2009) will simultaneously enhance stability and potency.
Notably, UNA-modified overhangs were found to dramatically
enhance the serum stability of otherwise unmodified siRNAs
in mouse serum leading to successful gene silencing in vivo,
whereas little difference in stability was seen in bovine serum
(Laursen et al., 2010) likely reflecting species differences in RNase
composition or serum preparation; As a note of caution, degra-
dation of siRNAs is faster in human than mouse serum sug-
gesting that future therapeutic application of unformulated siR-
NAs may prove more difficult in humans than in mouse models
(Haupenthal et al., 2006).
Alternatively, siRNAs may be stabilized by moderately enhanc-
ing their local thermodynamic stability to minimize the accessibil-
ity of vulnerable sequence-motifs exposed by thermal fluctuations,
e.g., the introduction of stabilizing LNA (Braasch et al., 2003;
Grunweller et al., 2003; Elmén et al., 2005; Mook et al., 2007; Bram-
sen et al., 2009) or 4′ thioribose (Dande et al., 2006) at selected
positions within the duplex can enhance siRNA stability while gen-
erally preserving siRNA potency. Notably, siRNAs are designed to
be thermodynamically asymmetric and hereby more“loose”in one
duplex end hereby rendering it particular exposed to endonuclease
attack, a problem that has been addressed by 2′-OMe modification
of loose regions (Hoerter and Walter, 2007).
ENHANCING SILENCING DURATION
The transient nature of gene silencing by synthetic siRNA poses
concerns for therapeutics as it will require repeated dosing at
short intervals. Such transience is primarily due to the contin-
uous dilution of the effective intracellular siRNA pool through
cellular proliferation and degradation; in cultures of proliferating
cells, silencing duration is most dependent on dilution through cell
division and silencing normally persists for no more than 2–7 days
whereas this period can be extended for several weeks in termi-
nally differentiated non-dividing cells, such as macrophages, and
up to 1 month in the slowly dividing CCD-1074Sk cells (Bartlett
and Davis, 2007). Encouragingly, this implies that silencing dura-
tion may be much longer in a therapeutic setting where target cells
usually are slowly or non-dividing and indeed long-lasting target
inhibition in the livers of mice and non-human primates have
been reported (Zimmermann et al., 2006).
SEQUENCE-DEPENDENT SILENCING DURATION
Small interfering RNA silencing duration appears to be sequence-
dependent and does not necessarily correlate with initial silenc-
ing efficacy (Strapps et al., 2010). The basis for such sequence-
dependency remains unresolved but may reflect multiple factors
such as the differences in intracellular stability of unbound siRNA,
their affinity for RNAi pathway components, reaction kinetics and
target (and off-target) levels (Arvey et al., 2010). Also, endogenous
proteins that bind siRNA and dampen silencing activity, such as
Eri-1 (Kennedy et al., 2004; Bian et al., 2011) and ADAR1 (Hong
et al., 2005), may have sequence-dependent affinities for siRNAs.
Notably, the expression of Eri-1 and ADAR1 are induced by high-
doses of siRNA and may account for the observation that higher
doses of siRNA in some instances had lower silencing duration
than lower doses both in cell cultures and in mouse livers upon
hydrodynamic injection (Hong et al., 2005; Bian et al., 2011).
ENHANCING siRNA SILENCING LONGEVITY BY CHEMICAL
STABILIZATION
Many studies attribute the prolonged silencing duration of chem-
ically modified siRNAs to their high nuclease resistance which
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would ensure delivery of more intact siRNAs into the cell and sub-
sequently stabilize the internalized siRNA pool available for RISC
recruitment. Several of the stabilizing modifications mentioned
above have also been reported to slightly enhance the duration
of silencing using 2′-OMe (Collingwood et al., 2008; Volkov et al.,
2009), F-ANA (Dowler et al., 2006), 2′-F (Chiu and Rana, 2003), or
complex modification schemes (Morrissey et al., 2005b), whereas
other studies do not find enhancement of silencing persistence
upon chemical stabilization (Layzer et al., 2004). A direct com-
parison of stabilized and unmodified siRNAs delivered by several
different methods in vitro and in vivo have suggested that the ben-
efits of chemical stabilization arise during siRNA delivery prior
to cellular internalization and that stabilization does not signifi-
cantly enhance silencing magnitude or persistence once siRNA are
located in the cytoplasm (Bartlett and Davis, 2007). Still, Taka-
hashi et al. (2012) reported that the higher intracellular stability
of a 2′-OMe-4′-Thio-modified siRNA, as evaluated by QPCR,
leads to long-term RNAi effect suggesting that previous mod-
ification schemes may not have provided sufficient stability to
significantly enhance silencing persistence. In agreement, Volkov
et al. (2009) found that prolonged silencing could only be iden-
tified in cell culture when all vulnerable dinucleotide motif were
2′-OMe-modified within the siRNA.
siRNA RECRUITMENT AND SILENCING DURATION
Notably, the industry-standard DNA overhangs, typically dTdT,
has been reported to significantly reduce silencing duration irre-
spectively of the siRNA sequence (Strapps et al., 2010) and it is
tempting to speculate that the reported sixfold higher affinity of
dTdT-siRNA for Ago2 (Maiti et al., 2011) may in fact reduce silenc-
ing duration as siRNAs are faster recruited and turned over than
lower affinity siRNAs. In accordance with this, rates for siRNA-
RISC complex formation is two times slower for blunt siRNAs
compared to canonical siRNA, whereas silencing persistence is
enhanced (Ghosh et al., 2009). Also, the dumbbell siRNA design
(Abe et al., 2007), which encompasses a 23-bp stem and 9-nt loops
at both ends, exhibits a prolonged silencing persistence poten-
tially because Dicer only very slowly processes RNA dumbbells
into siRNA species (Abe et al., 2011).
REDUCING siRNA IMMUNOGENICITY BY CHEMICAL
MODIFICATION
The original observation that synthetic 21-mer siRNA can trig-
ger sequence-specific mRNA degradation without apparent side-
effects in human cell cultures promised synthetic siRNA to
bedrock efficient and safe RNA therapeutics (Elbashir et al.,
2001a). This observation was especially appreciated as the intro-
duction of long dsRNA, a gene silencing strategy employed in
popular non-mammalian systems, had been precluded in mam-
mals by the induction of innate immune responses leading to
pro-inflammatory cytokine production and ultimately cell death
(Minks et al., 1979). It is becoming increasingly clear, however,
that unmodified synthetic siRNA can be triggers of innate immune
responses depending on their structure, sequence, target cell type,
entry route, formulation reagent used and concentration, despite
their structural mimicry of endogenous siRNA/miRNA species
(Sledz et al., 2003; Hornung et al., 2005; Judge et al., 2005; Sioud,
2005; Reynolds et al., 2006). A variety of proteins, commonly
referred to as pattern recognition receptors (PRRs), act as cellular
sensors of exogenous RNA both extra- and intracellularly, where
they monitor predefined hallmarks of foreign, typically viral, RNA
such as length, 5′-end triphosphates, sequence composition, heli-
cal structure, and end-groups (Sioud, 2009). Most important to
siRNA recognition are three members of the transmembrane Toll-
like Receptor (TLR) family, namely TLR3 and TLR7/8, which
recognize double or single-stranded RNA, respectively, primar-
ily in immune cells and endo and epithelial linings of the body, as
described below.
DETECTION OF siRNAs BY TLR3
TLR3 senses the length of exogenous dsRNA (Alexopoulou et al.,
2001) on the cell surface and in endosomes of dendritic cells,
epi-, and endothelial linings (Cario and Podolsky, 2000; Kleinman
et al., 2008; Lim et al., 2009; Zimmer et al., 2011; Taura et al.,
2012) and consequently in many primary cells and popular cell
lines (Kariko et al., 2004; Reynolds et al., 2006). Twenty-three
mer siRNAs were early reported to trigger low-level immuno-
genicity through TLR3 in HEK293 cells (Kariko et al., 2004), an
effect that was subsequently found highly duplex length and cell
type specific; Reynolds et al. (2006) found that canonical 21-mer
siRNAs did not trigger innate immune responses in human cell
lines whereas longer siRNAs (23–33 mer) led to concentration-
dependent, sequence-independent and presumably TRL3 medi-
ated interferon-responses in some cell lines (DU145, HeLa S3, and
MCF-7), but not in other cell lines (HeLa and Hek293 cells). In
agreement, a very comprehensive study shows that longer DsiR-
NAs are indeed more immunogenic than 21-mer siRNAs both
in vitro and in vivo (Foster et al., 2012) and that such dsiRNA
designs are therefore not suited for siRNA therapeutics in a chem-
ically non-modified form. Notably, sequence-independent activa-
tion of surface-bound TLR3 on retinal pigmented epithelial cells
has been reported in a murine choroidal neovascularization model
upon intraocular injection of naked 21-mer siRNAs (Kleinman
et al., 2008). Also, shorter 19-mer siRNA designs did not trigger
TLR3 activation, observations that were subsequently confirmed
in other mouse models (Cho et al., 2009; Berge et al., 2010).
PREVENTING ACTIVATION OF TLR3
The activation of murine TLR3 by unformulated 21-mer siRNAs
has raised natural concerns for future siRNA therapeutics. How-
ever, similar effects may not apply to human cells; Weber et al.
(2012) found that none of the tested TLR3 expressing human
cell lines were responsive to unformulated, naked 21-mer siRNA,
which may be due to sequence differences in the RNA binding
ectodomain among species (Ranjith-Kumar et al., 2007). Still,
researches may choose to use only 19-mer siRNA design that seem
non-immunogenic and accept the slightly reduced potency of this
siRNA platform or may instead choose to chemically modify the
21-mer siRNA structure to make it unrecognizable to TLR3, a task
that is currently ongoing. In this regard, activation of PKR, a cyto-
plasmic dsRNA sensor, has been abrogated in HeLa cells by site-
specific introduction of purine N2-benzyl modifications in the
siRNA passenger strand (Puthenveetil et al., 2006). Also, disrupting
the structure of a 47-bp dsRNA by introduction of GU wobble
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base pairs or introduction of 2′-deoxyuridine, 4-thiouridine, and
2-thiouridine (s2U) reduced PKR activation whereas 2′-F and PS
did not (Nallagatla and Bevilacqua, 2008). Such abrogation of PKR
activation suggests that chemical modification may similarly help
reduce potential TLR3 activation by 21-mer siRNA.
DETECTION OF siRNA BY ENDOSOMAL TLR7/8
Small interfering RNAs can, upon internalization by endocytosis,
be recognized by TLRs 7 and 8 (TLR7/8), which are transmem-
brane receptors exclusively found in the endosomes in different
leukocyte subsets; TLR7 is mainly expressed in plasmacytoid den-
dritic cells (pDCs) and B cells, whereas TLR8 is expressed in
monocyte-derived DCs (mDCs), monocytes, macrophages, or reg-
ulatory T cells (Hornung et al., 2002; Heil et al., 2004; Kokkinopou-
los et al., 2005). TLR7/8 are reported to recognize specific single-
stranded RNA motifs, which may be exposed from the siRNA
duplex upon random thermal fluctuations. A number of immune-
stimulatory GU- or U-rich motifs can trigger TLR7 activation such
as GUCCUUCAA (Judge et al., 2005), UGUGU (Sioud, 2006),
UGGC (Fedorov et al., 2006), UCA (Jurk et al., 2011), and GU
(Diebold et al., 2004; Heil et al., 2004) whereas AU-rich motif pri-
marily stimulate TLR8 (Forsbach et al., 2008). Collectively, such
motif all agrees with the consensus that multiple uridines in close
proximity are both necessary and sufficient for TLR7 stimulation
(Diebold et al., 2006) whereas the exact sequence requirement
and positional effects within the siRNA are not fully understood
(Gantier et al., 2008; Goodchild et al., 2009); In fact, a single
uridine may be sufficient to activate an immune response in a
5′-UCA-3′ sequence context whereas other uridine positions are
non-immunogenic (Jurk et al., 2011).
ABROGATING TLR7/8 ACTIVATION BY CHEMICAL MODIFICATION
Activation of endosomal TLR7/8 is currently considered the major
source of siRNA immunogenicity in vivo (Hornung et al., 2005;
Judge et al., 2005; Sioud, 2005; Cekaite et al., 2007; Robbins et al.,
2008; Zamanian-Daryoush et al., 2008), which suggest that most
siRNA immunogenicity may be avoided in human cells either
by using delivery method that prevents siRNA endosomal reten-
tion (Sioud, 2005; Inaba et al., 2012) or by rendering siRNAs
unrecognizable to TLR7/8 by chemical modification. The lat-
ter has been achieved by modifying the specific immunogenic
sequences within the siRNA duplex; typically, small 2′ OH sub-
stitution have been employed, such as 2′-F, 2′-H, and 2′-OMe, as
these can effectively abrogate TLR interaction while generally pre-
serving silencing activity even upon extensive modification. Most
efforts have focused on modifying U’s or U-rich regions within
either or both strands of the siRNA (Heil et al., 2004; Diebold
et al., 2006) as uridine residues are critical for siRNA activation
of TLR7/8 (Heil et al., 2004; Hornung et al., 2005; Diebold et al.,
2006; Eberle et al., 2008) and a significant correlation between the
U count and siRNA immunogenicity has been suggested (Diebold
et al., 2006; Goodchild et al., 2009). In fact, the rather com-
monly used UU overhangs can, in some cases, contribute to the
activation of TLR7/8 (Goodchild et al., 2009). Modification of
siRNA uridines with either 2′-F or 2′-OMe (Cekaite et al., 2007)
or deoxynucleotide residues (Eberle et al., 2008) has been sug-
gested as a general strategy to abrogate siRNA immunogenicity
while preserving siRNA potency; In this regard, 2′-F is slightly less
efficient in reducing siRNA immunogenicity than, e.g., 2′-OMe,
which conversely is more likely to reduce siRNA potency (Prakash
et al., 2005; Shin et al., 2007; Fucini et al., 2012). Notably, not only
uridine, but also guanidine and adenosine modification have been
reported to reduce siRNA immunogenicity, at least when a certain
threshold of modification is met, whereas cytidine modifications
have no effect (Hornung et al., 2005; Kariko et al., 2005; Morris-
sey et al., 2005b; Judge et al., 2006; Eberle et al., 2008; Fucini et al.,
2012; Ocampo et al., 2012). Recently, selective adenosine modifica-
tion, especially by 2′-OMe, has been recommended as it was found
to most consistently reduce immunogenicity upon both 2′-OMe
and 2′-F modification of different sequences (Robbins et al., 2007;
Fucini et al., 2012). Encouragingly, 2′-OMe is particular potent
in reducing siRNA immunogenicity (Robbins et al., 2007; Fucini
et al., 2012) and alternating 2′-OMe modification of the passen-
ger strand has been proposed as a universal approach to avoid
TLR7 activation as it does not reduce guide strand potency (Hamm
et al., 2009). This special property of 2′-OMe-modified RNA may
reflect it being a potent antagonist of TLR7 activation: even sin-
gle 2′-OMe modification can reduce immunogenicity in vitro and
in vivo (Tluk et al., 2009) and 2′-OMe-modified oligoes can reduce
the immunogenicity of other RNAs in trans upon co-transfection
(Robbins et al., 2007).
The strength of hybridization between the siRNA strands has
been suggested to correlate negatively with immunogenicity; inter-
spersed CG or GC clamps may inhibit TLR7/8 activation by
increasing siRNA thermostability and thereby impair the exposure
of stimulatory single-stranded RNA upon breathing (Goodchild
et al., 2009). Indeed, enhancing siRNA thermostability, e.g., by
moderate LNA modification even of the strand opposing the
putative immunogenic motif (Hornung et al., 2005; Goodchild
et al., 2009; Schyth et al., 2012), may reduce siRNA immunogenic-
ity by making the single-stranded immunogenic sequence-motif
inaccessible to TLR7/8 recognition.
Other modifications types have also been shown to reduce
TLR7/8 activation such as backbone PS modifications (Jurk
et al., 2011) and base modifications including 5-methylcytidine
(m5C), 5-methyluracil (m5U), N6-methyladenosine (m6A), s2U,
or pseudouridine (Kariko et al., 2005) but are not widely used due
to the success of other modification types, particularly 2′-OMe.
SENSORS OF CYTOPLASMIC siRNA
Cytoplasmic siRNAs, originating from endosomal release or direct
cytoplasmic transfection, are monitored by a number of cytoplas-
mic PRRs that, similarly to the TLRs, respond to predefined RNA
characteristics. A prominent sensor of dsRNA length is the dsRNA-
dependent protein kinase R (PKR) that was originally described to
sequence-independently act on dsRNA longer than 30 bp for reg-
ulation of cytokine expression in most cells types (Manche et al.,
1992). Later studies demonstrated that only 17 bp dsRNA could
activate PKR signal (Nanduri et al., 1998) and indeed modest PKR
activation by 21-mer siRNAs has been reported in, e.g., microglial
N9 (Zhang et al., 2006), T98G (Sledz et al., 2003; Marques et al.,
2006; Puthenveetil et al., 2006), HeLa (Puthenveetil et al., 2006),
MCF-7 (Armstrong et al., 2008), and HepG2.2.15 cells (Han
et al., 2011). RIG-I is another prominent sensor of cytoplasmic
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dsRNA that can recognize dsRNA as small as 25bp and 5′-end
triphosphates in a sequence-independent manner (Marques et al.,
2006; Takahasi et al., 2008). The canonical 21-mer siRNA design
having two 2 nt 3′ overhangs is tolerated, yet blunt 21–27-mer
siRNA can activate RIG-I (Marques et al., 2006). Also, melanoma
differentiation-associated gene 5 (Mda5) has been reported to
respond to siRNA (Kang et al., 2002).
The impact of modest cytoplasmic PRR activation needs to
be studied further, a task that is complicated by the complex
interplay of signaling pathways during innate immune responses.
Notably, direct cytoplasmic delivery of siRNA by electroporation
into human blood cells abrogated the siRNA immunogenicity
observed when delivering identical siRNAs via endosomes using
lipids, which suggests that synthetic siRNAs are rather detected
by TLRs than cytoplasmic sensors in immune cells (Sioud, 2005).
Therefore researches tend to focus more on reducing the potent
TLR-mediated responses during application in vivo. Still, PKR
activation can be reduced by chemical modification such as N2-
benzyl modifications (Puthenveetil et al., 2006) 2′-deoxyuridine,
4-thiouridine, and s2U (Nallagatla and Bevilacqua, 2008) as stated
above. The low RIG-I activity seen when using 21-mer siRNA
with canonical 2 nt 3′-overhang has left this pathway less studied,
however, blunt-ended siRNAs, such as some asymmetric dsiRNAs
designs, may be modified by 2′-OMe (Collingwood et al., 2008;
Zamanian-Daryoush et al., 2008) or DNA (Marques et al., 2006)
to reduce RIG-I activation.
REDUCING siRNA OFF-TARGET EFFECTS BY CHEMICAL
MODIFICATION
The high sequence specificity of siRNA action was immediately
praised as a major benefit of RNAi-based gene silencing. Indeed,
The RISC/Ago2-mediated cleavage of target RNAs by a matching
siRNA is highly sequence-specific allowing only few mismatches,
particularly at siRNA terminal ends (Du et al., 2005; Dahlgren
et al., 2008). Hereby cleavage of unintended targets can simply be
avoided during siRNA design by BLASTing candidate sequences
against the relevant transcriptome. Still, siRNA significantly influ-
ence the target cell transcriptome in a sequence and concentration-
dependent manner by triggering modest and unintended silencing
of hundreds of endogenous genes (Doench et al., 2003; Jackson
et al., 2003; Lim et al., 2005; Birmingham et al., 2006). Such so-
called off-target effects may immediately remain unnoticed, but
can lead to cellular toxicity (Fedorov et al., 2006), misinterpreta-
tion of an RNAi experiment (Lin et al., 2005), and are unacceptable
in a therapeutic setting.
Off-target effects reflect the shared handling of siRNA and
miRNA by the RNAi pathway, which inherently enable siRNAs
to behave as miRNAs (Doench et al., 2003). Hereby siRNA off-
targeting is primarily mediated by the interaction between the
seed region of the RISC-associated guide strand (positions 2–
7/8 counting from the 5′-end) and complementary sequences in
mRNA 3′-UTRs (Lin et al., 2005; Birmingham et al., 2006) leading
to translational inhibition and mRNA destabilization rather than
mRNA cleavage by Ago2 (Doench and Sharp, 2004; Wu et al., 2006;
Baek et al., 2008; Guo et al., 2010). Although off-target effects are
somewhat predictable and may be minimized by in silico analysis
(similar to miRNA target prediction) they cannot be fully avoided
and remain an inherent feature of unmodified siRNAs (Doench
et al., 2003; Jackson et al., 2006b). Off-target effects can be min-
imized by using the lowest possible dose of siRNAs sufficient for
efficient target KD (Jackson et al., 2003, 2006b) or by using siRNA
pools directed against multiple target sites in the same mRNA
to reduce the contribution of individual siRNAs to off-targeting
(Myers and Ferrell, 2005; Myers et al., 2006). Yet, the competition
between co-transfected siRNAs for incorporation into RISC com-
plicates this latter strategy (Castanotto et al., 2007). Furthermore,
as off-targeting can be mediated by both strands of the duplex
(Wei et al., 2009), designing siRNA with optimal thermodynamic
asymmetry will ensure preferential guide strand uptake into RISC
and reduce passenger strand off-targeting.
A more indirect type off-targeting comes from the compe-
tition between exogenous siRNA and endogenous miRNAs for
RNAi proteins; siRNA (and miRNAs) have different affinities for
RISC (Koller et al., 2006; Castanotto et al., 2007; Vickers et al.,
2007), which is reportedly determined by the siRNA seed sequence
(Yoo et al., 2008) and siRNAs can effectively compete out endoge-
nous miRNA leading to deregulated gene expression (Khan et al.,
2009). Also, thermodynamically stable siRNAs may be more slowly
processed by the RNAi machinery leading to clotting of the RNAi
pathway and natural gene regulation.
MINIMIZING PASSENGER STRAND OFF-TARGETING BY CHEMICAL
MODIFICATION
Owing to the structural symmetry of the canonical siRNA, both
strands may potentially contribute to off-targeting (Wei et al.,
2009), a matter that has been resolved by chemical modification.
For siRNAs designed with insufficient thermodynamic asymmetry
between duplex ends, selective unwinding of the siRNA from the
5′-end of the guide strand can be favored by introducing additional
asymmetric thermostability by chemical modification identical to
those that aim to enhance siRNA potency through selective guide
strand loading. Similarly, asymmetric chemical modification of
siRNA overhangs can disfavor passenger strand selection dur-
ing RISC loading to enhance silencing specificity (see Designing
Potent siRNAs by Chemical Engineering). Chemical modification
may also be employed to fully prevent loading of the passenger
strand: The 5′-phosphate of the passenger strand, required for
strand function (Nykanen et al., 2001), may be chemically blocked,
e.g., by 5′-OMe modification to prevent binding the AGO MID
domain (Chen et al., 2008). Similarly, a single UNA modification
at the 5′-terminus of the passenger strand can reduce unspecific
passenger strand activity (Vaish et al., 2011).
A radical approach to prevent passenger strand off-targeting is
to use alternative siRNA designs; aiRNAs or asiRNAs habour short-
ened passenger strands which cannot be efficiently loaded into
RISC (Chu and Rana, 2008; Sun et al., 2008; Chang et al., 2009)
whereas the three stranded sisiRNA design renders the passen-
ger strand non-functional by splitting it into two shorter strands
incapable of directing RNAi (Bramsen et al., 2007).
REDUCING OFF-TARGET EFFECTS BY MODIFYING THE GUIDE STRAND
SEED REGION
The initial interaction between the siRNA guide strand (or
miRNA) and target RNA is mediated by the seed region exposed
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by RISC (Wang et al., 2008). Therefore, mismatches in or chemical
modification of this region have a severe effect on the miRNA-like
interference that often relies only on seed matching (Birmingham
et al., 2006) whereas fully matched siRNAs can usually accom-
modate a single mismatch at selected seed positions without a
substantial loss of silencing efficacy (Du et al., 2005; Dahlgren
et al., 2008). Therefore position-specific modifications in the seed
region of the guide strand have been screened to reduce the siRNA
off-targeting potential while preserving siRNA effects though tar-
get cleavage. Jackson et al. (2006a) demonstrated that 2′-OMe
modification can site-specifically reduce off-targeting when posi-
tioned at guide strand position 2 without severe reductions in
siRNA potencies. A similar screen reported that substituting the
entire guide strand seed region, e.g., positions 1–8 with DNA
could also reduce off-targeting although the effects seemed more
sequence-specific (Ui-Tei et al., 2008). Recently, we showed that
incorporation of the strongly destabilizing UNA modification at
position 7 very potently eliminated off-target effects with minimal
negative impact on siRNA efficiency in three different siRNA tested
(Bramsen et al., 2010), a result subsequently confirmed by others
(Vaish et al., 2011). Although these finding greatly enhance the
therapeutic potential of siRNAs, it remains to be fully explored how
applicable these modification principles are translated to RNAi
in vivo.
ALTERNATIVE MEANS TO REDUCE OFF-TARGETING
Off-targeting by siRNA may also be reduced by insuring that
siRNAs are primarily loaded into RISC complexes harboring the
cleavage-competent Ago2 in contrast to Ago1, -3, or -4-containing
RISC, which would not allow target cleavage, but merely miRNA-
like effects. Synthetic siRNA duplexes interact with all Ago pro-
teins, yet the non-catalytic Ago1, -3, and -4 can be selectively inhib-
ited by stabilizing siRNA with LNA hereby leading to increased
silencing activity via Ago2-RISC and potentially less off-targeting
(Petri et al., 2011). Also, the perturbance of endogenous miRNA
pathways upon siRNA transfection may quite naturally be mini-
mized by using a minimal amount of siRNAs (Khan et al., 2009).
Alternatively, chemical modification has been shown to influ-
ence siRNA competitive powers (Yoo et al., 2008) and chemical
modification schemes that ensure sufficient silencing with a min-
imum of miRNA pathway perturbance are likely to be established
soon.
FINAL REMARKS: BUILDING AND MAKING GOOD USE OF
CHEMICALLY OPTIMIZED siRNAs
There is little doubt that chemical engineering can bring siRNAs
closer to clinical success and, as explored throughout this text,
it is now fairly well established how chemical modification can
enhance siRNA potency, nuclease resistance, and reduce siRNA
immunogenicity and off-targeting. However, the difficulty of effi-
cient and targeted siRNA delivery in vivo represents the major bot-
tleneck for broader clinical application and concurrently hampers
the evaluation and further chemical refinement of siRNA perfor-
mance and it seems that more immediate clinical success is pivotal
to maintaining the high momentum in siRNA drug development.
In this regard, implementation of promising local delivery systems
by smaller RNAi R&D companies may prove most promising,
while universal systemic delivery strategies, commercialized by
major Pharma industries, are more distant goals.
Very extensively or fully modified siRNAs have typically been
most successful in vivo during early development of chemi-
cally modified siRNAs (Soutschek et al., 2004) but may also be
inhibitory to rapid advances into clinical testing due to higher cost
and availability of the modified nucleotides. However, the initial
reports from clinical application suggests that high modification
levels may not always be needed, even for unformulated siRNAs
(Leachman et al., 2010), and the concurrent use of protective
siRNA delivery vehicles predicts that siRNA modification levels
may be kept relatively low. While awaiting more clinical success of
siRNA therapeutics our knowledge of natural gene silencing path-
ways is expanding and particularly the regulation and deregulation
of miRNAs expression in human diseases hold diagnostic, prog-
nostic and therapeutic value. Strategies for replenishing reduced or
lost miRNA expression in human disease by introducing miRNA
mimics or inhibiting aberrantly expressed miRNAs via synthetic
anti-miRs is currently gaining momentum (Bader et al., 2010).
As synthetic siRNA and miRNA mimic are practically identical,
the huge arsenal of chemical modification schemes developed for
siRNAs will greatly aid the fast development of synthetic miRNA
therapeutics in the years to come.
A QUICK GUIDE TO CHEMICAL siRNA DESIGN
In Figure 4 we summarize our own general strategy for siRNA
design and modification, which aim to keep modification levels
low. Whereas this may serve as an inspiration to fellow siRNA
researchers, experimental validation of function in vivo is still
needed and one may still consider utilizing more extensive and
well-characterized modification schemes (as described in the text
above).
We recommend that siRNA should be designed by first select-
ing the desired siRNA type; here the canonical 21-mer siRNA
has been extensively tested and has produced potent and safe
gene silencing in vivo although the concerning TLR3 activa-
tion observed in mice may need further evaluation in human
cells. The primary siRNA sequence should be chosen to target
highly accessible regions within the target RNA as the siRNA
thermo-stability profile can subsequently be tweaked by chemical
modification, whereas no modification types have been reported
to improve siRNA performance on poorly accessible target. To
optimize specificity, siRNA should not share extensive sequence
complementarity to non-intended targets and off-targets base-
pairing to siRNA positions 2–16 should preferentially be avoided.
siRNAs should be designed to be thermodynamically asymmet-
ric, preferably by primary sequence selection of A/U base-paring
at positions 1–2 and G/C base-pairing at position 19 of the
guide strand. To introduce additional thermodynamic asymmetry,
destabilizing modification can be introduced in the passenger 3′-
end or stabilizing modification in the 5′-end, if needed. Similarly,
asymmetric overhang modification can affect strand selection to
enhance siRNA potency and specificity and modestly enhance
nuclease resistance, whereas dTdT overhangs should be avoided
as they reduce silencing longevity. Also, the incorporation of the
passenger strand into RISC can be fully avoided by blocking its 5′-
phosphate group. Importantly, miRNA-like off-targeting is best
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FIGURE 4 | Suggested siRNA design scheme. Please see text for details.
reduced by introducing UNA at position 7 of the guide strand,
but 2′-OMe and DNA modification of the guide strand seed
have also proved efficient. siRNA immunogenicity and nuclease
resistance may likely be simultaneously addressed by chemical
modification with 2′-OMe and 2′-F, possibly in combination
with limited PS backbone or 4′-Thio modification. As 2′-OMe
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modification may fully abrogate TLR7/8 responses, nuclease sen-
sitive sites (primarily UA and CA) may be modified by 2′-OMe
in the passenger strand to enhance siRNA stability while abro-
gating immunogenicity. As 2′-OMe may not be well-tolerated
in the guide strand seed, 2′-F modification should instead be
used at nuclease sensitive sites in this region. Alternatively, both
nuclease resistance and immunogenicity may be addressable by
slightly enhancing siRNA thermodynamic stability, e.g., by LNA
modifications.
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